Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes.

ABSTRACT:

Objective

The high degree of clinical overlap between atypical parkinsonian syndromes (APS) and Parkinson's disease (PD) makes diagnosis challenging. We aimed to identify novel diagnostic protein biomarkers of APS using multiplex proximity extension assay (PEA) testing.

Methods

Cerebrospinal fluid (CSF) samples from two independent cohorts, each consisting of APS and PD cases, and controls, were analysed for neurofilament light chain (NF-L) and Olink Neurology and Inflammation PEA biomarker panels. Whole-cohort comparisons of biomarker concentrations were made between APS (n=114), PD (n=37) and control (n=34) groups using logistic regression analyses that included gender, age and disease duration as covariates.

Results

APS versus controls analyses revealed 11 CSF mark

SUBMITTER: Jabbari E 

PROVIDER: S-EPMC6585258 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature